[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kras-g12c-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kras-g12c-lung-cancer":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,82],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100577047",false,"NCT06793215","A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","Krascendo 2","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Histologically or cytologically confirmed diagnosis of advanced or metastatic non squamous NSCLC that is not eligible for curative surgery and\u002For definitive chemoradiotherapy\n* Measurable disease, as defined by RECIST v1.1\n* No prior systemic treatment for advanced or metastatic NSCLC\n* Documentation of the presence of a KRAS G12C mutation\n* Documentation of known PD-L1 expression status in tumor tissue\n* Availability of a representative tumor specimen\n* Adequate end-organ function\n* Eligible to receive a platinum-based chemotherapy regimen\n\nExclusion Criteria Related to NSCLC:\n\n* Known concomitant second oncogenic driver with available targeted treatment\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Spinal cord compression not definitively treated with surgery and\u002For radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \\>=2 weeks prior to randomization\n* History of leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once a month or more frequently)\n\nExclusion Criteria Related to Current or Prior Treatments:\n\n* Any anti-cancer systemic therapy, including hormonal therapy, within 21 days prior to randomization, or is expected to require any other form of antineoplastic therapy while in the study\n* Radiation therapy including palliative RT to bone metastases within 2 weeks prior to randomization and RT to the lung \\>30Gy within 6 months prior to randomization\n* Prior treatment with KRAS G12C inhibitors or pan-KRAS\u002FRAS inhibitors\n* Treatment with systemic immunosuppressive or immunostimulatory medications, including CD137 agonists and immune checkpoint inhibitors\n* Current treatment with medications that are well known to prolong the QT interval\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to randomization\n* Prior allogeneic stem cell or solid organ transplantation\n\nExclusion Criteria Related to General Health:\n\n* History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival \\[OS\\] rate \\>90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer\n* Individuals with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or any active bowel inflammation (including diverticulitis), malabsorption syndrome, conditions that would interfere with enteral absorption\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest computed tomography scan\n* Significant cardiovascular disease within 3 months prior to screening","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).",[26,27],"Non-Small Cell Lung Cancer","KRAS G12C Lung Cancer",[29,30,31,32,33,34,35,36,37,38],"Advanced Non-Small Cell Lung Cancer","KRAS G12 Lung Cancer","Advanced Lung Cancer","Metastatic lung cancer","Divarasib","KRAS G12C Inhibitor","KRAS G12C Positive","KRAS Mutation","KRAS G12C Mutation","Lung Cancer Mutation","RECRUITING","2026-06-05",{"date":42,"type":43},"2026-06-09","ACTUAL",{"date":45,"type":43},"2025-10-24",{"date":47,"type":20},"2030-10-31",{"name":49,"class":50},"Hoffmann-La Roche","INDUSTRY",251,{"id":53,"slug":4,"hasResults":10,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100629269","NCT07472478","Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","An Exploratory Phase II Clinical Study Protocol of Perioperative Treatment With Glesorasib Sequentially Combined With Ivonescimab and Chemotherapy for Resectable, Stage IB-IIIB, KRAS G12C-Mutant NSCLC","GIVEN","Inclusion Criteria:\n\n1. Age Range: Males or females aged 18 years or older.\n2. Diagnosis and Stage: Patients with histologically or cytologically confirmed resectable IB-IIIB NSCLC, staged according to the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology, 9th Edition.\n3. Informed Consent: Patients must voluntarily participate in the study, provide written informed consent, and be willing to comply with follow-up procedures.\n4. Prior Therapy: No prior systemic therapy for locally advanced or metastatic NSCLC (including adjuvant chemo\u002Fradiotherapy, neoadjuvant chemo\u002Fradiotherapy, definitive chemoradiotherapy, chemotherapy, radiotherapy, immune checkpoint inhibitors, targeted therapy, or anti-angiogenic therapy for locally advanced disease).\n5. Mutation Status: KRAS G12C mutation positivity must be confirmed by next-generation sequencing (NGS) or polymerase chain reaction (PCR) testing.\n6. Measurable Disease: At least one measurable target lesion as per RECIST v1.1. Lesions previously treated with radiotherapy or other local-regional therapies cannot be considered target lesions unless clear progression has been documented post-radiotherapy. At baseline, the lesion must be ≥10mm in the longest diameter (≥15mm in short axis for lymph nodes) on CT or MRI and be suitable for accurate repeated measurement per RECIST v1.1.\n7. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n8. Adequate Organ Function: Must meet the following criteria within 14 days prior to relevant tests, without transfusion or use of hematopoietic growth factors:\n\n   1. Platelets (PLT) ≥90 × 10\\^9\u002FL\n   2. Hemoglobin (HGB) ≥90 g\u002FL\n   3. Absolute Neutrophil Count (ANC) ≥1.5 × 10\\^9\u002FL\n   4. Serum creatinine ≤1.5 × ULN or Creatinine Clearance (CrCl) ≥50 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n   5. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN if liver metastases are present)\n   6. Total Bilirubin (TBIL) ≤1.5 × ULN (≤3 × ULN for patients with Gilbert's syndrome)\n   7. International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 × ULN, and Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN, or patients assessed by the investigator as having controlled bleeding tendency.\n   8. Urinalysis showing urine protein \\\u003C2+ or 24-hour urinary protein quantification \\\u003C1g.\n9. Life Expectancy: Expected survival time ≥3 months.\n10. Contraception: Fertile female subjects must agree to use effective contraception (e.g., IUD, oral contraceptives, condoms) during the study and for 6 months after study completion; have a negative serum pregnancy test within 7 days before enrollment; and must not be breastfeeding. Male subjects must agree to use effective contraception during the study and for 6 months after study completion.\n\nExclusion Criteria:\n\n1. Prior Anti-Tumor Therapy:\n\n   1. Previous receipt of any anti-tumor therapy for lung cancer (including adjuvant chemoradiotherapy, neoadjuvant chemoradiotherapy, chemotherapy, radiotherapy, immune checkpoint inhibitors, targeted therapy, anti-angiogenic therapy, etc.).\n   2. Treatment with any other investigational drug within 28 days prior to the first dose in this study.\n   3. Treatment within 2 weeks prior to the first dose with NMPA-approved Chinese patent medicines explicitly indicated for anti-tumor purposes in their drug说明书 (e.g., Compound Banmao Capsules, Kang'ai Injection, Kanglaite Capsules\u002FInjection, Aidi Injection, Yadanzi Oil Injection\u002FCapsules, Xiaoaiping Tablets\u002FInjection, Huachansu Capsules, etc.).\n2. Recent Surgery: Any surgery within 4 weeks prior to screening examinations.\n3. Concurrent Primary Malignancy: Patients with a concurrent primary malignancy (except for adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, etc.).\n4. Abnormal Organ Function: Meeting any of the following at screening:\n\n   1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5 times the upper limit of normal (ULN).\n   2. Creatinine clearance rate (CrCl) \\> ULN.\n5. Hematological Abnormalities: Total white blood cell (WBC) count \\> 10.0 × 10\\^9\u002FL or \\\u003C 1.0 × 10\\^9\u002FL at screening.\n6. Significant Comorbidities: History of immunodeficiency diseases (e.g., HIV), other active cancers or malignancy history, autoimmune diseases, severe cardiovascular or cerebrovascular diseases, or any other diseases that may significantly reduce life expectancy.\n7. Conditions Affecting Compliance: Any history of conditions that may affect protocol compliance (e.g., severe psychiatric disorders, cognitive dysfunction, drug abuse or addiction).\n8. Pregnancy, Lactation, and Contraception: Pregnant or lactating women, or subjects of childbearing potential unwilling or unable to use effective contraception.\n9. Allergy: Known allergy to any component of the study drug(s).\n10. Recent Trial Participation: Participation in any drug clinical trial within 6 months prior to screening.\n11. Investigator's Discretion: Any condition considered by the investigator as unsuitable for study participation.\n12. Other Driver Mutations: Non-small cell lung cancer with other standard-therapy-eligible driver gene mutations (e.g., EGFR, ALK, BRAF V600E, HER-2, MET Exon 14, ROS1, RET, or NTRK1\u002F2\u002F3).\n13. Central Nervous System (CNS) Metastases:\n\n    1. Symptomatic or progressive CNS metastases or carcinomatous meningitis.\n    2. Subjects with a history of brain metastases may be considered if they are clinically stable: no neurological symptoms, no corticosteroid treatment required, no indication for radiotherapy, and the largest diameter of the largest metastatic lesion on recent imaging is ≤ 1.5 cm.\n    3. Asymptomatic CNS metastases newly discovered during screening are allowed.\n    4. Subjects with a history of asymptomatic CNS metastases require confirmation of no progression via imaging scans performed at least 2 weeks apart.\n    5. Subjects with symptomatic CNS metastases may be considered if clinically stable after radiotherapy and\u002For surgery.\n    6. Subjects who underwent surgery for CNS metastases must have an interval of at least 4 weeks before the first study dose.\n    7. Asymptomatic subjects after CNS radiotherapy must have discontinued corticosteroids for at least 2 weeks prior to the first dose.\n14. Cardiovascular Disease: Any of the following:\n\n    1. Congestive heart failure of New York Heart Association Class II or above.\n    2. Severe arrhythmia requiring medication.\n    3. Acute myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass graft within 6 months prior to enrollment.\n    4. Left ventricular ejection fraction (LVEF) \\\u003C 50%.\n    5. Prolonged QTcF interval ( \\> 470 ms for females, \\> 450 ms for males) or risk factors for Torsades de Pointes.\n    6. Uncontrolled hypertension (systolic BP ≥ 150 mmHg and\u002For diastolic BP ≥ 100 mmHg after antihypertensive therapy).\n15. Thromboembolic Events: Arterial\u002Fvenous thrombotic events within 6 months, hypertensive crisis, or hypertensive encephalopathy.\n16. History of Epilepsy: Previous history of epilepsy.\n17. Superior Vena Cava Syndrome: Presence of superior vena cava syndrome.\n18. Pulmonary Disease: Active non-infectious interstitial lung disease, radiation pneumonitis, etc., active tuberculosis, pneumoconiosis, ≥ Grade 2 other pneumonias, or severely impaired pulmonary function at screening.\n19. Severe Bone Lesions: Existing or potential severe bone damage from metastases, or uncontrolled bone pain.\n20. Active Infection: Active or uncontrolled severe infection, or unexplained fever \\> 38.5°C.\n21. Third-Space Fluid: Poorly controlled or drainage-requiring pleural effusion, ascites, or pericardial effusion. Subjects stabilized after treatment may be enrolled.\n22. Tumor Invading Major Vessels: Imaging shows tumor invading or with unclear boundaries to major blood vessels.\n23. Bleeding Risk: Evidence or history of bleeding tendency within 2 months before the first dose; history of hemoptysis, or unhealed wounds\u002Fulcers\u002Ffractures within 2 weeks before the first dose.\n24. Gastrointestinal Diseases: Known GI impairment or diseases significantly affecting drug absorption\u002Fmetabolism, or major GI surgery affecting absorption.\n25. Recent Live Vaccination: Administration of a live attenuated vaccine within 4 weeks before the first dose.\n26. Severe Hypersensitivity to mAbs: History of severe hypersensitivity reaction to other monoclonal antibodies.\n27. Autoimmune Disease: Active autoimmune disease requiring systemic treatment within 2 years before the first dose.\n28. Immunosuppressive Therapy: Receiving systemic corticosteroids or other immunosuppressive therapy.\n29. Viral Infections: Positive HIV antibody, or active viral hepatitis.\n\n    1. Active Hepatitis B or active Hepatitis C.\n    2. Carriers require antiviral therapy and monitoring during the study.\n30. Active Syphilis.\n31. Renal Failure: Requiring hemodialysis or peritoneal dialysis.\n32. Poorly Controlled Diabetes: Fasting blood glucose \\> 10 mmol\u002FL.\n33. Organ Transplant: History of or planned organ transplantation.\n34. Recent Major Surgery\u002FTrauma: Major surgery or significant trauma within 4 weeks before the first dose.\n35. Recent Radiotherapy: Palliative radiotherapy within 2 weeks before the first dose.\n36. Residual Toxicity from Prior Therapy: Toxicities from previous anti-cancer therapy not recovered to Grade ≤1.\n37. Other: Any other clinically significant abnormality or disease deemed by the investigator to pose risk or interfere with the study.","80 Years",{"count":61,"type":20},32,[63],"PHASE2","This study is a multicenter, prospective, open-label clinical trial. It enrolls previously untreated patients with resectable stage IB-IIIB KRAS G12C mutation-positive NSCLC to evaluate the efficacy and safety of glesorasib sequentially combined with ivonescimab and chemotherapy as perioperative treatment for this patient population.",[66,27],"Lung Cancer (NSCLC)",[68,69,70],"lung cancer","KRAS","KRAS G12C","NOT_YET_RECRUITING","2026-03-13",{"date":74,"type":43},"2026-03-16",{"date":76,"type":20},"2026-03-15",{"date":78,"type":20},"2028-03-31",{"name":80,"class":81},"Guangdong Provincial People's Hospital","OTHER",{"id":83,"slug":4,"hasResults":10,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100588073","NCT06936644","A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation","Inclusion Criteria:\n\n1. Sign the Informed Consent Form (ICF) and be able to comply with the visit and related procedures as stipulated in the protocol.\n2. Be male or female, aged ≥18 and ≤75 years old.\n3. Have an expected survival time of ≥6 months.\n4. Have histologically or cytologically confirmed locally advanced (IIIB\u002FIIIC stage), metastatic or recurrent (IV stage) non-small cell lung cancer (NSCLC) that is not operable and not suitable for radical concurrent chemoradiotherapy, as classified by the 8th edition of the TNM staging system of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer.\n5. All subjects must have a written test report before enrollment to prove the presence of KRAS G12C mutation; and must have no sensitive mutations of Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK), or other gene mutation types approved by the National Medical Products Administration (NMPA) for first-line treatment of NSCLC.\n6. Have at least one measurable lesion according to RECIST 1.1 criteria.\n7. Have not received any systemic anti-tumor treatment for locally advanced or metastatic NSCLC before; previous adjuvant therapy is allowed, but the interval between the last adjuvant therapy or last radical radiotherapy and disease recurrence should be at least 6 months.\n8. Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n9. Have adequate organ and bone marrow function (subjects who have received any cell or growth factor therapy within 2 weeks before the first administration of the study drug should be excluded), defined as follows:\n\n1\\) Blood routine: Absolute neutrophil count (ANC) ≥1.5×109\u002FL or within the normal range; platelet (PLT) count ≥100×109\u002FL; hemoglobin (HGB) content ≥9.0 g\u002FdL.\n\n2\\) Liver function: Serum total bilirubin (TBIL) ≤1.5×Upper Limit of Normal Value (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN.\n\n3\\) Renal function: Serum creatinine (Cr) ≤1.5×ULN or clearance of creatinine (CCr) ≥50 mL\u002Fmin, calculated by the Cockcroft-Gault formula (using actual body weight); urine routine test shows urine protein \\\u003C2+; for subjects with urine protein ≥2+ at baseline as detected by urine test strips, a 24-hour urine collection should be performed and the protein content in 24-hour urine should be \\\u003C1 g (if both methods are used, the value obtained from 24-hour urine collection will be used to determine eligibility). 4) Coagulation function: Activated Partial Thromboplastin Time (APTT) ≤ 1.5×ULN and International Normalized Ratio (INR) ≤ 1.5; 10. Female subjects of childbearing age or male subjects whose partners are of childbearing age must take effective contraceptive measures throughout the treatment period and for 180 days after the treatment.\n\n11\\. Female subjects have evidence of postmenopausal status, or the urine or serum pregnancy test results of premenopausal female subjects are negative.\n\nExclusion Criteria:\n\nSubjects should not be enrolled in this study if they meet any of the following criteria:\n\n1\\. Histological or cytological pathology confirms the presence of small cell carcinoma, neuroendocrine carcinoma, sarcoma, lymphoepithelioma-like carcinoma, salivary gland tumors, or mesenchymal tumor components.\n\n2\\. Have significant cardiovascular or cerebrovascular diseases, such as:\n\n1. Experienced definite cardiovascular abnormal events within 6 months, such as myocardial infarction, angina pectoris, heart failure, severe arrhythmia, or undergone angioplasty, vascular stent implantation, coronary artery bypass surgery, etc.\n2. Have clinically significant QT\u002FQTcF interval prolongation (QTcF \\> 470ms for females or \\> 450ms for males).\n3. Experienced definite cerebrovascular abnormal events within 3 months, such as cerebral hemorrhage or cerebral infarction.\n\n3\\. Active central nervous system metastases (such as brain metastases or leptomeningeal metastases) are not eligible for enrollment. For subjects with brain metastases who have received radiotherapy or local treatment, if no hormones or antiepileptic drugs are used, they must be asymptomatic within at least 7 days after radiotherapy to be eligible for enrollment; if hormones or antiepileptic drugs are used, they must be asymptomatic within at least 7 days after drug withdrawal and the investigator deems the brain metastases to be stable, they can be eligible for enrollment; if stable brain metastases patients have not received radiotherapy or hormone or antiepileptic drug treatment, they can be eligible for enrollment after the investigator deems the brain metastases to be stable.\n\n4\\. Currently have clinically significant interstitial lung disease, radiation pneumonitis, drug-related pneumonitis, active pulmonary tuberculosis, pneumoconiosis, or have ≥ grade 2 other types of pneumonia, or have severe lung function impairment confirmed by pulmonary function tests (FEV1 or DLCO or DLCO\u002FVA \\\u003C 40% of predicted values).\n\n5\\. Have significant gastrointestinal diseases, such as intractable hiccups, nausea, vomiting, severe gastrointestinal ulcers, liver cirrhosis, active gastrointestinal bleeding, or other diseases that affect swallowing tablets or significantly affect the absorption of oral drugs.\n\n6\\. Have major acute or chronic infections, including:\n\n1. Active infections requiring systemic treatment;\n2. Positive human immunodeficiency virus antibody (HIV-Ab) at baseline, acute or chronic active hepatitis B (defined as positive HBsAg and\u002For HBcAb and HBV-DNA copy number higher than 2500 copies\u002Fml or 500IU\u002Fml), or acute or chronic active hepatitis C (positive HCV antibody and HCV-RNA higher than the detection limit of the analytical method);\n3. Active pulmonary tuberculosis. 7. Accompanied by recurrent drainage or refractory pleural or peritoneal effusion or pericardial effusion.\n\n8\\. Accompanied by other poorly controlled systemic diseases, such as uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg) or diabetes despite standard treatment.\n\n9\\. Have a history of significant bleeding tendency or coagulation disorders; have significant clinical bleeding symptoms within 4 weeks before enrollment, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing or expectorating ≥ 1 teaspoon of fresh blood or small blood clots or only coughing blood without sputum, subjects with blood in sputum are allowed to enroll), nasal bleeding (excluding epistaxis and retracted nasal blood); imaging studies during the screening period show that the tumor surrounds important blood vessels or has obvious necrosis or cavities, and the investigator deems that enrollment in the study would cause a bleeding risk.\n\n10\\. Tumor invades or compresses surrounding important organs (such as the aorta, heart and pericardium, superior vena cava, trachea, esophagus, etc.) or has a risk of esophagotracheal fistula or esophagopleural fistula; mediastinal lymph node metastasis of the tumor invades the trachea or main bronchus. 11. Participants with other malignant tumors within 2 years before entering the study, except for appropriately treated cervical carcinoma in situ, focal cutaneous squamous cell carcinoma, basal cell carcinoma, prostate cancer that does not require treatment, ductal carcinoma in situ of the breast, and superficial non-muscle-invasive urothelial carcinoma.\n\n12\\. Participants who have previously received KRAS G12C inhibitor treatment. 13. Participants who have previously received immunotherapy, including immune checkpoint inhibitors (such as anti-PD-1\u002FL1 antibodies, anti-CTLA-4 antibodies, etc.), immune checkpoint agonists (such as ICOS, CD40, CD137, GITR, OX40 antibodies, etc.), and any other treatments targeting tumor immune mechanisms.\n\n14\\. Participants who have previously received systemic anti-angiogenic therapy, including but not limited to bevacizumab and its biosimilars, endostar, small molecule TKIs, ramucirumab, etc.\n\n15\\. Participants who have received systemic treatment with traditional Chinese medicine with anti-tumor indications within 1 week before the first dose or with drugs that have immunomodulatory effects within 2 weeks before the first dose (including thymosin, interferon, interleukin, except for local use to control pleural effusion).\n\n16\\. Participants who have received therapeutic or palliative radiotherapy (excluding cranial radiotherapy) or local treatment within 14 days before the first dose of this study.\n\n17\\. Participants who have received chemotherapy, targeted therapy, immunotherapy, other investigational drugs or investigational devices, or other anti-tumor treatments within 28 days or 5 half-lives (whichever is shorter) before the first dose of this study.\n\n18\\. Participants who have undergone surgery that may affect the administration or evaluation of this study within 28 days before enrollment (excluding biopsy).\n\n19\\. Participants who have received known CYP2D6, CYP3A4, P-gp, and BCRP sensitive substrates within 14 days or 5 half-lives (whichever is longer) before the first dose of this study, and the therapeutic window of the substrate is narrow, unless agreed by the investigator and the sponsor to be enrolled.\n\n20\\. Participants who are simultaneously involved in another interventional clinical study, except for observational (non-interventional) clinical studies or those in the follow-up stage after the end of an interventional study.\n\n21\\. Participants who have used immunosuppressive drugs within 4 weeks before the first dose of study treatment, excluding nasal sprays, inhalation or other local routes of glucocorticoids or systemic glucocorticoids at physiological doses (i.e., no more than 10mg\u002Fday of prednisone or equivalent doses of other glucocorticoids), or glucocorticoids used to prevent contrast agent allergy.\n\n22\\. Participants who have received live attenuated vaccines within 4 weeks before the first dose of study treatment or plan to receive them during the study period.\n\n23\\. Note: Inactivated virus vaccines for seasonal influenza by injection are allowed within 4 weeks before the first dose of study treatment; however, live attenuated influenza vaccines are not allowed.\n\n24\\. Participants with known or suspected autoimmune diseases or a history of such diseases within the past 2 years (participants with vitiligo, psoriasis, alopecia, or Graves' disease that did not require systemic treatment in the past 2 years, hypothyroidism requiring only thyroid hormone replacement therapy, and type 1 diabetes requiring only insulin replacement therapy can be enrolled).\n\n25\\. Participants with active or a history of definite inflammatory bowel disease (such as Crohn's disease, ulcerative colitis, or chronic diarrhea).\n\n26\\. Participants with a known history of primary immunodeficiency. 27. Participants with a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n\n28\\. Participants with a history of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolic event within 3 months before enrollment (implantable venous access ports or catheter-related thrombosis, or superficial venous thrombosis are not considered \"serious\" thromboembolic events).\n\n29\\. Participants with known allergies to study treatment or any of its components.\n\n30\\. Pregnant or lactating women. 31. Other situations that the researcher deems unsuitable for participation in this study.","75 Years",{"count":89,"type":20},39,[63],"A multicenter, single-arm Phase II study to evaluate the efficacy and safety of fulzerasib (IBI351) in combination with ivonescimab (AK-112) in first-line treatment of advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation",[27],"2025-04-14",{"date":95,"type":43},"2025-04-20",{"date":97,"type":20},"2025-04-30",{"date":99,"type":20},"2028-03-30",{"name":101,"class":81},"Shanghai Chest Hospital",""]